- Joint Presentation Will Focus on Strategic Significance of Merger -
PRINCETON, N.J., and SOUTH SAN FRANCISCO, Jan. 8 /PRNewswire/ --
Pharmacopeia, Inc. (Nasdaq: PCOP) and Eos Biotechnology (Eos) today announced
that they will make a joint presentation at the JPMorgan H&Q Healthcare
Conference on January 9, 2002 at 4:30 p.m. PST. Joseph A. Mollica, Ph.D.,
Pharmacopeia's Chairman, President, and CEO, and David W. Martin, Jr., M.D.,
Eos' President and CEO will speak on behalf of the companies. The conference
is taking place at the Westin St. Francis Hotel in San Francisco, California.
The joint presentation will focus on the individual strengths of each
company and the powerful drug discovery and development engine that would be
created by joining the scientists, management, technology, science, and
product pipelines of both companies. The presentation will be available for
replay on Pharmacopeia's website at http://www.pcop.com. Additional information on
Pharmacopeia and Eos can be found at their respective websites at http://www.pcop.com
and http://www.eosbiotech.com.
PHARMACOPEIA URGES INVESTORS AND SECURITY HOLDERS TO READ THE PROXY
STATEMENT/PROSPECTUS REGARDING PHARMACOPEIA'S PROPOSED ACQUISITION OF EOS
BIOTECHNOLOGY, AS IT CONTAINS IMPORTANT INFORMATION. Security holders may
receive a free copy of the proxy statement/prospectus, as well as other
related documents filed by Pharmacopeia, at the Web site of the Securities and
Exchange Commission (the "SEC"), http://www.sec.gov. In addition, copies of
documents filed with the SEC by Pharmacopeia can be obtained, without charge,
by directing a request to MacKenzie Partners by email to:
proxy@mackenziepartners.com or call (800) 322-2885 or to Pharmacopeia Investor
Relations at P.O. Box 5350, Princeton, NJ 08543-5350, or (609) 452-3600.
Pharmacopeia (http://www.pharmacopeia.com) provides enabling science and
technology that accelerates and improves the drug discovery and chemical
development processes. Pharmacopeia's Drug Discovery segment integrates
proprietary small molecule combinatorial and medicinal chemistry, high-
throughput screening, in-vitro pharmacology, computational methods and
informatics to discover and optimize lead compounds. Pharmacopeia's software
subsidiary, Accelrys, develops and commercializes molecular modeling and
simulation software for the life sciences and materials research,
cheminformatics and decision support systems, and bioinformatics tools
including gene sequence analysis. The business also provides consulting
services to its customers in drug discovery and chemical development.
Pharmacopeia employs approximately 800 people, generated 2000 revenues of
approximately $119 million, and is headquartered in Princeton, NJ.
Eos Biotechnology, Inc., a privately funded biotechnology company in South
San Francisco, California, develops, applies and integrates a variety of high-
throughput genomics, bioinformatics and biological processes for the creation
of novel therapeutic and diagnostic products. Eos technologies are being
applied to rapidly and cost-effectively build a pipeline of novel and
medically important therapeutics and diagnostics in the areas of oncology,
angiogenesis and inflammation, with initial product development efforts
focused in the area of therapeutic antibodies.
When used anywhere in this document, the words "expects", "believes",
"anticipates", "estimates" and similar expressions are intended to identify
forward-looking statements. Forward-looking statements herein may include
statements addressing future financial and operating results of Pharmacopeia
and the timing, benefits and other aspects of the proposed merger.
Pharmacopeia has based these forward-looking statements on its current
expectations about future events. Such statements are subject to risks and
uncertainties including, but not limited to, the successful implementation of
Pharmacopeia's strategic plans, the acceptance of new products, the
obsolescence of existing products, the resolution of existing and potential
future patent issues, additional competition, changes in economic conditions,
and other risks described in documents Pharmacopeia has filed with the SEC,
including its most recent report on Form 10-K and subsequent reports on Form
10-Q. All forward-looking statements in this document are qualified entirely
by the cautionary statements included in this document and such filings.
These risks and uncertainties could cause actual results to differ materially
from results expressed or implied by forward-looking statements contained in
this document. These forward-looking statements speak only as of the date of
this document. Pharmacopeia disclaims any undertaking to publicly update or
revise any forward-looking statements contained herein to reflect any change
in its expectations with regard thereto or any change in events, conditions or
circumstances on which any such statement is based.
SOURCE Pharmacopeia, Inc.
 back to top
Related links:
http://www.pharmacopeia.com
CONTACT:
Sue Rodney, Manager, Investor Relations of
Pharmacopeia, +1-609-452-3643, or srodney@pharmacop.com
|
